ExoLytics is an early-stage biotechnology startup focused on developing novel, innovative, and disruptive technologies to combat drug-resistant infectious diseases. The company harnesses endolysins, enzymes present in nature, to engineer safe, rapid, and effective antimicrobial therapies.
The rise in antimicrobial drug resistance, coupled with shrinking treatment options, will challenge global public health and create new, untapped, market opportunities. ExoLytics intends to play a critical role in worldwide efforts to develop and commercialize alternatives to antibiotics.
For company news and key events, please subscribe with your email address:
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.